Limitations to the killing of tumours using radiolabelled antibodies

Andrew T M Vaughan, P. Anderson, P. W. Dykes, C. E. Chapman, A. R. Bradwell

Research output: Contribution to journalArticle

78 Scopus citations

Abstract

We have calculated the minimum requirements for effective therapy using intravenously administered, tumour-directed antibodies labelled with either iodine 131 or yttrium 90. A lethally large amount of either radionuclide would be required to achieve tumour destruction. At least a 10-fold increase in tumour uptake is necessary to combine tumour destruction with a survivable whole-body dose. The required improvement in specific uptake can be substantially reduced by accelerating the excretion of radioactivity outside the tumour. For all situations studied, yttrium 90 is superior to iodine 131 as a cytotoxic label.

Original languageEnglish (US)
Pages (from-to)567-572
Number of pages6
JournalBritish Journal of Radiology
Volume60
Issue number714
StatePublished - 1987
Externally publishedYes

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Limitations to the killing of tumours using radiolabelled antibodies'. Together they form a unique fingerprint.

  • Cite this

    Vaughan, A. T. M., Anderson, P., Dykes, P. W., Chapman, C. E., & Bradwell, A. R. (1987). Limitations to the killing of tumours using radiolabelled antibodies. British Journal of Radiology, 60(714), 567-572.